S100P and hepatocellular carcinoma: Finally, prospective multicenter trials should evaluate liquid biopsy applications, particularly for the 14-gene HBV signature (ABCA8, S100P) and 164 cirrhosis-to-HCC transition markers, benchmarked against current standards like AFP.